

1 **Primary tumor associated macrophages activate programs of invasion and dormancy in**
2 **disseminating tumor cells.**

3

4 Lucia Borriello^{1,2}, Anouchka Coste^{1,3}, Brian Traub^{1,3}, Ved P. Sharma^{1,2,4}, George S. Karagiannis^{2,5}, Yu
5 Lin^{1,2}, Yarong Wang^{1,2}, Xianjun Ye^{1,2,4}, Camille L. Duran^{1,2}, Xiaoming Chen^{1,2,4}, Madeline Friedman¹,
6 Maria Soledad Sosa⁶, Dan Sun^{7,8}, Erica Dalla⁹, Deepak K. Singh^{7,8}, Maja H. Oktay^{1,2,4,10}, Julio A. Aguirre-
7 Ghiso^{*,2,4,7,8}, John S. Condeelis^{*,1,2,3,4}, and David Entenberg^{*,1,2,4,8,10}

8

9 ¹ Department of Anatomy and Structural Biology, Albert Einstein College of Medicine / Montefiore Medical
10 Center, Bronx, NY, USA

11 ² Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine / Montefiore Medical Center,
12 Bronx, NY, USA

13 ³ Department of Surgery, Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY,
14 USA

15 ⁴ Integrated Imaging Program, Albert Einstein College of Medicine / Montefiore Medical Center, Bronx,
16 NY, USA

17 ⁵ Department of Microbiology and Immunology, Albert Einstein College of Medicine / Montefiore Medical
18 Center, Bronx, NY, USA

19 ⁶ Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,
20 USA

21 ⁷ Department of Cell Biology, Albert Einstein College of Medicine / Montefiore Medical Center, 1300
22 Morris Park Avenue, Bronx, NY 10461, USA

23 ⁸ Cancer Dormancy and Tumor Microenvironment Institute, Einstein Cancer Center, Albert Einstein
24 College of Medicine/ Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY 10461, USA

25 ⁹ Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,
26 New York, NY, USA

27 ¹⁰ Department of Pathology, Einstein College of Medicine / Montefiore Medical Center, Bronx, NY, USA





28

29 *** Corresponding Authors:**

30 David Entenberg: david.entenberg@einsteinmed.edu

31 John Condeelis: john.condeelis@einsteinmed.edu

32 Julio Aguirre-Ghiso: julio.aguirre-ghiso@einsteinmed.edu



35 **Supplementary Figure 1: Disseminated Tumor Cells Remain within an Imaging Field of View**
36 **throughout an 8 hr Period.**


37 **a:** Representative intravital microscopy images showing intravascular disseminated tumor cells at
38 different time points spanning 8 hrs. Red=tdTomato labeled endothelial cells and 155 kDa
39 Tetramethylrhodamine dextran labeled blood serum, Green=GFP labeled tumor cells. **Rightmost Panel:**
40 Outlines of the tumor cell at t=0 (green) and t=8 hr (red) showing net displacement. Scale bar=15 μm .

41 **b:** Representative intravital microscopy images showing extravascular disseminated tumor cells at
42 different time points spanning 8 hrs. Red=tdTomato labeled endothelial cells and 155 kDa
43 Tetramethylrhodamine dextran labeled blood serum, Green=GFP labeled tumor cells. **Rightmost Panel:**
44 Outlines of the tumor cell at t=0 (green) and t=8 hr (red) showing net displacement. Scale bar=15 μm .

45 **c:** Traces tracking the migration of intravascular E0771-GFP cells within SM (left) and EM (right) models
46 over an 8 hr period of time. Each tracked tumor cell is represented in a plot with the initial position (t=0
47 hrs) translated to the origin so as to provide an overview of the migration path of each cell. Red dashed
48 box indicates a full field of view in the microscope ($512 \times 512 \mu\text{m}^2$). Insets are zoom-ins of the central 150
49 μm . Average cell velocities: SM= $1.2 \pm 0.1 \mu\text{m/hr}$; EM= $1.7 \pm 0.1 \mu\text{m/hr}$; mean \pm SEM. SM: n=11 tumor
50 cells in 4 mice. EM: n=22 tumor cells in 2 mice.

51 **d:** Traces tracking the migration of extravascular E0771-GFP cells within SM (left) and EM (right) models
52 over an 8 hr period of time. Each tracked tumor cell is represented in a plot with the initial position (t=0
53 hrs) translated to the origin so as to provide an overview of the migration path of each cell. Red dashed
54 box indicates a full field of view in the microscope ($512 \times 512 \mu\text{m}^2$). Insets are zoom-in of the central 150
55 μm . Average cell velocities: SM= $2.0 \pm 0.2 \mu\text{m/hr}$; EM = $1.8 \pm 0.2 \mu\text{m/hr}$ mean \pm SEM. SM: n=7 tumor cells
56 in 4 mice. EM: n=11 tumor cells in 3 mice. Source data are provided as a Source Data file.

Supp. Figure 2



58 **Supplementary Figure 2: Tumor Cells that Spontaneously Disseminate from the Primary Tumor**
59 **to the Lung have a Drastically Increased Metastatic Efficiency Compared to Intravenously Injected**
60 **Tumor Cells**

61 **a:** Kaplan-Meier survival curves showing the percentage of 231-GFP disseminated tumor cells observed
62 under the WHRIL at each 8 hr time point over a period of 64 hours. EM: n=95 tumor cells analyzed in 4
63 mice. SM: n=67 tumor cells analyzed in 3 mice. Log-rank (Mantel-Cox) test (p=0.023). *p<.05.

64 **b:** Percentage of 231-GFP EM and SM tumor cells observed under the WHRIL that extravasated between
65 0 and 64 hrs after arrival. EM: n=37 tumor cells in 4 mice. SM: n=33 tumor cells in 3 mice. Bar=mean.
66 Error bars=±SEM. Two-tailed unpaired t-test (p=0.39). ns=not significant.


67 **c:** Quantification of the time from arrival under the WHRIL to extravasation into the lung parenchyma for
68 each 231-GFP EM and SM tumor cell. **Left:** EM: n=35 tumor cells in 4 mice. **Right:** SM: n=33 tumor cells
69 in 3 mice.

70 **d: Left:** Representative immunofluorescence images of Mena^{INV} expression in extravascular 231-GFP
71 tumor cells in the lung of an EM model (**top**) and an SM model (bottom). Green arrow: Mena^{INV} negative
72 tumor cell. Red arrow: Mena^{INV} positive tumor cell. Scale bar=50 μm. **Right:** Zoomed in view of yellow
73 boxed area of a disseminated tumor cell in both models. Green=GFP, Red=Mena^{INV}, White=endomucin,
74 Blue=DAPI. Scale bar=10 μm.

75 **e:** Quantification of extravascular Mena^{INV} positive disseminated tumor cells in the lung of each group
76 from D. EM: n=58 cells in 6 animals. SM: n=85 cells in 6 animals. Bar=mean. Error bars=±SEM. Two-
77 tailed unpaired t-test (p=0.045). *p<0.05.

78 **f:** Percentage of extravascular 231-GFP disseminated tumor cells that died, survived, or grew after
79 extravasation in EM and SM models 64 hrs after arrival to the lung vasculature. Bar=mean. Error
80 bars=±SEM. EM: n=35 tumor cells in 4 mice. SM: n=33 tumor cells in 3 mice. For the Died and Survived
81 columns, a two-tailed unpaired t-test was used (p=0.014 and p=0.015, respectively). For the Grew
82 columns, a two-tailed Mann-Whitney test was used (p=0.43). *p<0.05; ns=not significant. Source data
83 are provided as a Source Data file.







Supp. Figure 3



84

85 **Supplementary Figure 3: Spontaneously Circulating Tumor Cells Are Positive for NR2F1 When**
86 **Arriving in the Lung Vasculature**
87 **a:** Representative immunofluorescence image of NR2F1 expression in circulating tumor cells in lung
88 vasculature from a E0771-GFP SM model. n=1. **Left:** GFP channel. **Right:** NR2F1 channel. Green=GFP,
89 Red=NR2F1, Blue=DAPI. Dotted line indicates the boundary of the vasculature. CTC=Circulating Tumor
90 Cell. Scale bar=10 μ m.

Supp. Figure 4



92 **Supplementary Figure 4: Spontaneously Metastasizing Tumor Cells Are More Frequently Positive**
93 **for Dormancy and Stem-like Markers Compared to Intravenously Injected Tumor Cells**

94 **a:** Representative immunofluorescence images of NR2F1 expression in primary tumors, circulating tumor
95 cells (CTCs), and disseminated tumor cells (Lung) from a 231-GFP SM model (**Left**) and in disseminated
96 tumor cells (Lung) from an EM model (**Right**). Green=GFP, Red=NR2F1, Blue=DAPI. Scale bar for
97 Primary Tumor=50 μm . Scale bar for CTCs and Lung=15 μm .

98 **b:** Percentage of NR2F1-positive and negative tumor cells in each group in Supplemental Figure 4a.
99 Primary Tumor: n=2,729 cells in 100 fields of view ($65 \times 65 \mu\text{m}^2$) in 6 animals; CTCs: n=166 cells in 5
100 animals; SM Lung: n=113 cells in 6 animals; In vitro: n= 261 cells in 3 independent experiments. EM
101 Lung: n=133 cells in 7 animals. Bar=mean. Error bars= \pm SEM. For PT vs. CTC ($p < 0.0001$), PT vs. Lung
102 SM ($p = 0.0005$), and CTC vs. Lung SM ($p = 0.0003$) a two-tailed one-way ANOVA test with Sidak's multiple
103 comparisons adjustment was used. For in vitro vs. Lung EM ($p = 0.99$) and Lung SM vs. Lung EM
104 ($p = 0.036$), a two-tailed Kruskal-Wallis test with Dunn's multiple comparisons adjustment as used.
105 *= $p < 0.05$. **= $p < 0.01$. ***= $p < 0.001$. ****= $p < 0.0001$. ns=not significant.

106 **c:** Representative immunofluorescence images of SOX9 expression in primary tumors, circulating tumor
107 cells (CTCs), and disseminated tumor cells (Lung) from a 231-GFP SM model (**Left**) and in disseminated
108 tumor cells (Lung) from an EM model (**Right**). Green=GFP, Red=SOX9, Blue=DAPI. Scale bar for
109 Primary Tumor=50 μm . Scale bar for CTCs and Lung=15 μm .

110 **d:** Percentage of SOX9^{High} tumor cells from each group in Supplemental Figure 4c. Primary Tumor:
111 n=2,643 cells in 100 fields of view ($65 \times 65 \mu\text{m}^2$) in 5 animals; CTCs: n=93 cells 3 animals, SM Lung: n=93
112 cells in 5 animals; EM Lung: n=99 cells in 6 animals. In vitro: n=576 cells in 6 independent experiments.
113 Bar=mean. Error bars= \pm SEM. For PT vs. CTC ($p < 0.0001$), PT vs. Lung SM ($p < 0.0001$), CTC vs. Lung
114 SM ($p = 0.22$), and Lung SM vs. Lung EM ($p < 0.0001$), a two-tailed ANOVA test with Sidak's multiple
115 comparisons adjustment was used. For in vitro vs. Lung EM ($p = 0.31$), a Mann-Whitney Test was used.
116 ****= $p < 0.0001$. ns=not significant.








117 **e:** Representative images of triple immunofluorescence staining for GFP, NR2F1, and SOX9^{High}
118 expression in primary tumors, circulating tumor cells (CTCs), and disseminated tumor cells (Lung) from
119 a 231-GFP SM model (**Left**) and in disseminated tumor cells (Lung) from an EM model (**Right**).
120 Green=GFP; Red=NR2F1; Orange=SOX9; Blue=DAPI. Scale bar for Primary Tumor=50 μm . Scale bar
121 for CTCs and Lung=15 μm .

122 **f:** Percentage of double positive (NR2F1-positive and SOX9^{High}) tumor cells from each group in
123 Supplemental Figure 4e. Primary Tumor: n=2,140 cells in 95 fields of view ($65 \times 65 \mu\text{m}^2$) in 5 animals;
124 CTCs: n=199 cells in 7 animals; SM Lung: n=242 cells in 10 animals; In vitro: n=320 cells in 3 independent
125 experiments. EM Lung: n=90 cells in 4 animals. Bar=mean. Error bars= \pm SEM.

126 For all comparisons, a two-tailed one-way ANOVA test with Sidak's multiple comparison adjustment was
127 used. PT vs. CTC: $p = 0.034$), PT vs. Lung SM ($p = 0.0027$), CTC vs. Lung SM ($p = 0.89$), Lung SM vs. Lung

128 EM (p=0.046), and in vitro vs. Lung EM (p=1.00). *=p<0.05; **=p<0.01; ns=not significant. Source data
129 are provided as a Source Data file.

Supp. Figure 5



131 **Supplementary Figure 5: *In Vivo* Regulation of the Fate of DTCs by NR2F1.**

132 **a:** Representative images of MDA-MB-231-GFP-shRNAmir-NR2F1 cells cultured *in vitro* with, or without,
133 doxycycline (DOX, 0.5 µg/mL). Green=GFP; Red=doxycycline shRNAmir-NR2F1. Scale bar 20 µm.

134 **b:** Western blot of MDA-MB-231-GFP-shRNAmir-NR2F1 cells treated with or without doxycycline (DOX,
135 0.5 µg/ml). β-Actin was used as a loading control.

136 **c:** qPCR data for NR2F1 from MDA-MB-231-GFP-shRNAmir-NR2F1 cells treated with or without
137 doxycycline (DOX, 0.5 µg/ml). n=3 RNA replicates per condition. Two-tailed unpaired t-test (p=0.0034).
138 **=p<0.01.



139 **d:** Outline of the experimental design for knocking down NR2F1 in 231-GFP-shRNAmir-NR2F1 tumor
140 cells nude mice with doxycycline to determine the impact of NR2F1 expression on tumor cell
141 extravasation and growth.

142 **e:** Percentage of MDA-MB-231-GFP-shRNAmir-NR2F1 cells treated with or without doxycycline that
143 extravasated between 0 and 24 hrs after iv injection. Without Dox: n=47 cells in 3 mice. With Dox: n=51
144 tumor cells in 3 mice. Bar=mean. Error bars=±SEM. Two-tailed unpaired t-test (p=0.027). *=p<0.05.

145 **f:** Number of metastatic foci (≥5 tumor cells) counted in the lungs of nude mice intravenously injected
146 with MDA-MB-231-GFP-shRNAmir-NR2F1 tumor cells and treated with or without doxycycline. Mice were
147 treated with or without doxycycline (25 mg/kg) every other day for the entire experimental design. Without
148 Dox: n=3 mice. With Dox: n=3 mice. Error bars =±SEM. For 4 days, a two-tailed unpaired t-test was used
149 (p=0.13). For 8 days, a Kruskal-Wallis test was used (p=0.05). *=p<0.05; ns=not significant.



150 **g:** Number of metastatic foci (≥5 tumor cells) counted in the lungs of mice bearing a primary tumor and
151 treated with or without doxycycline (25 mg/kg) every other day for the entire experimental design. Without
152 Dox n=3 mice. With Dox: n=3. Error bars =±SEM. For both 4 days (p=0.62) and 8 days (p=0.014), a two-
153 tailed unpaired t-test was used. *=p<0.05; ns=not significant. Source data are provided as a Source Data
154 file.

a



155

156 **Supplementary Figure 6: Serial Sections of E0771-GFP Primary Tumor Tissue Stained for TMEM**
157 **Doorways and GFP, NR2F1, and Mena^{INV}.**
158 **a: Left:** Representative image of E0771-GFP primary tumor stained for TMEM doorways with a triple
159 immunohistochemistry stain used for distance analysis shown in Figure 6b&c. Cells composing TMEM
160 are positioned at vertices of yellow triangle: Pink=Mena expressing tumor cells; Brown=IBA-1 expressing
161 macrophages; Blue=Endomucin expressing endothelial cells. Red dashed circle encompasses the
162 perimeter of TMEM doorway. Scale bar=60 μ m. **Right:** Tissue section sequential to Left
163 immunofluorescently stained for GFP (not shown for clarity), Mena^{INV}, and, NR2F1: Green=Mena^{INV}; Red
164 NR2F1; Blue=DAPI. Red dashed circle encompasses the perimeter of TMEM doorway. Red arrow points
165 to an NR2F1 and Mena^{INV} double positive tumor cell. n=eight regions of interest (1-3 mm²) in 4 mice.




167 **Supplementary Figure 7: Spontaneously Disseminated Tumor Cells Are Positive for NR2F1 and**
168 **Mena^{INV}.**



169 **a:** Representative images of triple immunofluorescence staining for GFP, NR2F1, and Mena^{INV}
170 expression in disseminated tumor cells (DTCs) and at different stages of metastatic progression: small
171 micro-metastases (≤ 10 cells), medium micrometastases (11-300 cells) and large micrometastases (≥ 300
172 cells) in an E0771-GFP SM model. Green=GFP; Orange=Mena^{INV}; Red=NR2F1; Blue=DAPI. Scale
173 bar=20 μm for disseminated tumor cell and 100 μm for micrometastases.

174 **b:** Quantification of NR2F1 and Mena^{INV} expression in single disseminated tumor cells (DTCs) and lung
175 metastases at different stages of metastatic progression as shown in Supplemental Figure 7a.
176 Disseminated tumor cells: n=452 cells in 5 animals. n=43 metastases analyzed in 5 mice. Bar=mean.
177 Error bars= \pm SEM. Source data are provided as a Source Data file.

Supp. Figure 8



179 **Supplementary Figure 8: Macrophages Regulate Dormancy in Disseminating Tumor cells**
180 **a:** Representative immunofluorescence images of NR2F1 expression in E0771-GFP tumor cells cultured
181 in a transwell system either alone (**Left**), together with macrophages (**Middle**), or together with
182 endothelial cells (**Right**). Green=GFP; Red=NR2F1; Blue=DAPI. Scale bar=15 μm .
183 **b:** Percentage of NR2F1-positive tumor cells from each group in Supplemental Figure 8a. TC alone:
184 n=734 cells in 6 independent experiments; TC + M ϕ ; n=686 cells in 4 independent experiments. TC +
185 EC; n=1,370 cells in 6 independent experiments. Bar=mean. Error bars= \pm SEM. For all comparisons a
186 two-tailed one-way ANOVA test with Tukey's multiple comparisons adjustment was used. TC vs. TC +
187 M ϕ : p=0.012, TC vs. TC + EC: p=0.95, TC + M ϕ vs. TC + EC: p=0.007. * $=p<0.05$.; ns=not significant.
188 TC=Tumor Cell. M ϕ =macrophage. EC=Endothelial Cell.
189 **c:** Representative immunofluorescence images of 231-GFP primary tumor tissues treated for 7 days with
190 either control liposomes or clodronate liposomes and stained for macrophages: IBA-1=White;
191 DAPI=Blue. Scale bar for Tumor=100 μm . M ϕ =Macrophage.
192 **d:** Number of IBA-1 positive macrophages in 10 fields of view (960x568 μm^2) in each group from
193 Supplemental Figure 8c. Control Liposomes: n=50 fields of view in 5 animals. Clodronate liposomes:
194 n=60 fields of view in 6 animals. Two-tailed unpaired t-test (p=0.046).* $=p<0.05$. Bar=mean. Error
195 bars= \pm SEM.
196 **e:** Representative immunofluorescence images of NR2F1 expression in primary tumors, circulating tumor
197 cells (CTCs), and disseminated tumor cells (Lung) from a 231-GFP SM model treated with control
198 liposomes (**Left**) or with clodronate liposomes (**Right**). Green=GFP, Red=NR2F1, Blue=DAPI. Scale bar
199 for Primary Tumor=50 μm . Scale bar for CTCs and Lung=15 μm .
200 **f:** Percentage of NR2F1-positive tumor cells in each group from Supplemental Figure 8e. Control
201 Liposomes - Primary Tumor: n=2,033 cells in 88 fields of view (65x65 μm^2) in 5 animals; CTCs: n=256
202 cells in 7 animals; Lung: n=98 cells in 4 animals. Clodronate Liposomes - Primary Tumor: n=2,829 cells
203 in 109 fields of view (65x65 μm^2) in 6 animals; CTCs: n=337 cells in 6 animals; Lung: n=126 cells in 6
204 animals. Bar=mean. Error bars= \pm SEM. For Primary tumor columns (p=0.0087), a two-tailed Mann
205 Whitney test was used. For CTCs (p=0.017) and Lung (p=0.043) columns, a two-tailed unpaired t-test
206 was used.* $=p<0.05$. ** $=p<0.01$. ns=not significant. Source data are provided as a Source Data file.





208 **Supplementary Figure 9: Quantification of CD11c⁺ Cells in Primary Tumors.**

209 **a:** Representative immunofluorescence images of E0771-GFP primary tumor tissues treated for 7 days
210 with either control or clodronate liposomes and stained for dendritic cells (CD11c⁺ IBA-1⁻). White=CD11c;
211 Red=IBA-1; Blue=DAPI. Mφ=Macrophage. Scale bar =50 μm.

212 **b:** Percentage of CD11c positive and IBA-1 negative dendritic cells in 10 fields of view (486x236 μm²) in
213 each group from E0771-GFP primary tumor tissues. Control Liposomes: n=40 fields of view in 4 animals.
214 Clodronate liposomes: n=40 fields of view in 4 animals. Bar=mean. Error bars=±SEM. Two-tailed
215 unpaired t-test (p=0.85). ns=not significant.


216 **c:** Percentage of CD11c positive and IBA-1 negative dendritic cells in 10 fields of view (486x287 μm²) in
217 each group from MDA-MB-231-GFP primary tumor tissues. Control Liposomes: n=40 fields of view in 4
218 animals. Clodronate liposomes: n=40 fields of view in 4 animals. Error bars=±SEM. Two-tailed unpaired
219 t-test (p=0.61). ns=not significant. Source data are provided as a Source Data file.

Supp. Figure 10



220

221 **Supplementary Figure 10: Expression of NR2F1 in MMTV-PyMT Tumors Wild-Type and Knock-**
222 **Out for Mena.**
223 **a:** Representative immunofluorescence images of MMTV-PyMT primary tumors that are wild-type (**Left**),
224 or knock-out for Mena (**Right**), and stained for NR2F1. Green=NR2F1; Red=PyMT. Scale bar=50 μm .
225 **b:** Quantification showing the intensity of nuclear NR2F1 expression in MMTV-PyMT primary tumors that
226 are wild-type or knock-out for Mena. MMTV-PyMT primary tumor wild-type: n=2,756 cells in 47 fields of
227 view (65x65 μm^2) in 3 animals. MMTV-PyMT primary tumor Mena knock-out: n=2,553 cells in 45 fields
228 of view (65x65 μm^2) in 3 animals. Bar=mean. Error bars= \pm SEM. Two-tailed unpaired t-test
229 ($p=0.039$). $*$ = $p<0.05$. Source data are provided as a Source Data file.



231 **Supplementary Figure 11: Systemic Depletion of Macrophages Reduces Tumor Cell Retention,**
232 **Extravasation, and Survival of DTCs in a SM Model.**



233 **a:** Outline of the experimental design. GFP labeled tumor cells were injected into the mammary gland
234 and tumors allowed to develop for ~4 weeks after which the WHRIL was surgically implanted and the
235 mouse allowed to recover for 24 hrs. After that, mouse was treated with control or clodronate liposomes
236 and imaged every 8 hrs for a period of 64 hrs.

237 **b:** Kaplan-Meier survival curves showing the percentage of E0771-GFP tumor cells observed under the
238 WHRIL at each 8 hr time point over a period of 64 hrs in mice treated with control or clodronate liposomes,
239 and in experimental metastasis (EM) and spontaneous metastasis (SM) models. EM and SM are same
240 data from Figure 1c, for comparison. Control Liposomes: n=81 tumor cells analyzed in 6 mice. Clodronate
241 Liposomes: n=32 tumor cells analyzed in 3 mice. EM: n=62 tumor cells analyzed in 3 mice. SM: n=28
242 tumor cells analyzed in 3 mice. Log-rank (Mantel-Cox) tests. EM vs. SM: $p < 0.0001$, EM vs. Clodronate
243 Liposomes: $p = 0.11$, Clodronate Liposomes vs. Control Liposomes: $p < 0.0001$, and Control Liposomes vs.
244 SM: $p = 0.19$. ****= $p < 0.0001$. ns=not significant.

245 **c:** Percentage of E0771-GFP tumor cells observed under the WHRIL that extravasated between 0 and
246 64 hrs after arrival in mice treated with control or clodronate liposomes, and in experimental metastasis
247 (EM) and spontaneous metastasis (SM) models. EM and SM are same data from Figure 1d, for
248 comparison. Control Liposomes: n=81 tumor cells analyzed in 6 mice. Clodronate Liposomes: n=32 tumor
249 cells analyzed in 3 mice. EM: n=89 tumor cells analyzed in 4 mice. SM: n=29 tumor cells analyzed in 3
250 mice. Bar=mean. Error bars= \pm SEM. For all comparisons, a two-tailed one-way ANOVA test with Sidak's
251 multiple comparisons adjustment was used. EM vs. SM: $p = 0.0036$, EM vs. Clodronate Liposomes:
252 $p = 0.57$, Clodronate Liposomes vs. Control Liposomes: $p = 0.014$, and Control Liposomes vs. SM: $p = 0.99$.
253 *= $p < 0.05$. **= $p < 0.01$. ns=not significant.

254 **d:** Percentage of extravascular E0771-GFP disseminated tumor cells that died or survived after
255 extravasation in mice treated with control or clodronate liposomes, and in experimental metastasis (EM)
256 and spontaneous metastasis (SM) models. EM and SM are same data from Figure 3b, for comparison.
257 Control Liposomes: n=54 tumor cells in 6 mice. Clodronate Liposomes: n=10 tumor cells in 3 mice. EM:
258 n=27 tumor cells analyzed in 4 mice. SM: n=31 tumor cells analyzed in 4 mice. Bar=mean. Error
259 bars= \pm SEM. For all comparisons, a two-tailed one-way ANOVA test with Sidak's multiple comparisons
260 adjustment was used. For Died: EM vs. SM: $p < 0.0001$, EM vs. Clodronate Liposomes: $p = 0.98$,
261 Clodronate Liposomes vs. Control Liposomes: $p = 0.0003$, and Control Liposomes vs. SM: $p = 0.52$. For
262 Survived: EM vs. SM: $p < 0.0001$, EM vs. Clodronate Liposomes: $p = 0.99$, Clodronate Liposomes vs.
263 Control Liposomes: $p = 0.0003$, and Control Liposomes vs. SM: $p = 0.52$. ***= $p < 0.001$. ****= $p < 0.0001$.
264 ns=not significant. Source data are provided as a Source Data file.

Supp. Figure 12







265

266 **Supplementary Figure 12: Quantification of IBA-1⁺ macrophages in primary breast tumors of**
267 **MaFIA mice.**

268 **a:** Representative immunofluorescence images of E0771-GFP primary tumor tissues treated for 7 days
269 with either control (**Left**) or B/B homodimerizer (**Right**), and stained for macrophages: White=IBA-1;
270 Blue=DAPI. Scale bar =50 μm . M ϕ =Macrophage.

271 **b:** Percentage of IBA-1 positive macrophages in 10 fields of view (963x570 μm^2) in each group of treated
272 E0771 primary tumor tissues. Control: n=30 fields of view in 3 animals. B/B homodimerizer: n=30 fields
273 of view in 3 animals. Bar=mean. Error bars= \pm SEM. Two-tailed unpaired t-test (p=0.0011). **=p<0.01.
274 Source data are provided as a Source Data file.

Supp. Figure 13



276 **Supplementary Figure 13: Macrophage Depletion with B/B Homodimerizer in MaFIA Mice Reduces**
277 **Tumor Cell Retention, Extravasation, and Survival of DTCs in the Lung.**


278 **a:** Outline of the experimental design. GFP labeled tumor cells were injected into the mammary gland
279 and tumors allowed to develop for ~4 weeks after which the WHRIL was surgically implanted and the
280 mouse allowed to recover for 24 hrs. After that, mouse was treated with control or B/B homodimerizer
281 and imaged every 8 hrs for a period of 64 hrs.

282 **b:** Kaplan-Meier survival curves showing the percentage of E0771-GFP tumor cells observed under the
283 WHRIL at each 8 hr time point over a period of 64 hrs in mice treated with control or B/B homodimerizer,
284 and in experimental metastasis (EM) and spontaneous metastasis (SM) models. EM and SM are same
285 data from Figure 1c, for comparison. Control: n=44 tumor cells analyzed in 3 mice. B/B: n=28 tumor cells
286 analyzed in 3 mice. EM: n=62 tumor cells analyzed in 3 mice. SM: n=28 tumor cells analyzed in 3 mice.
287 Log-rank (Mantel-Cox) tests. EM vs. SM: $p < 0.0001$, EM vs. B/B: $p = 0.15$, Control vs. B/B: $p = 0.0022$, and
288 Control vs. SM: $p = 0.092$. ****= $p < 0.0001$. **= $p < 0.01$. ns=not significant.

289 **c:** Percentage of E0771-GFP tumor cells observed under the WHRIL that extravasated between 0 and
290 64 hrs after arrival in mice treated with control or B/B homodimerizer, and in experimental metastasis
291 (EM) and spontaneous metastasis (SM) models. EM and SM are same data from Figure 1d, for
292 comparison. Control: n=44 tumor cells analyzed in 3 mice. B/B: n=28 tumor cells analyzed in 3 mice. EM:
293 n=89 tumor cells analyzed in 4 mice. SM: n=29 tumor cells analyzed in 3 mice. Bar=mean. Error
294 bars= \pm SEM. For all comparisons, a two-tailed one-way ANOVA test with Sidak's multiple comparisons
295 adjustment was used. EM vs. SM: $p = 0.018$, EM vs. B/B: $p = 1.0$, Control vs. B/B: $p = 0.028$, and Control vs.
296 SM: $p = 1.0$. *= $p < 0.05$. ns=not significant.

297 **d:** Percentage of extravascular E0771-GFP disseminated tumor cells that died or survived after
298 extravasation in mice treated with control or B/B homodimerizer, and in experimental metastasis (EM)
299 and spontaneous metastasis (SM) models. EM and SM are same data from Figure 3b, for comparison.
300 Control: n=27 tumor cells in 3 mice. B/B homodimerizer: n=6 tumor cells in 3 mice. EM: n=27 tumor cells
301 analyzed in 4 mice. SM: n=31 tumor cells analyzed in 4 mice. Bar=mean. Error bars= \pm SEM. For Control
302 vs. SM and for SM vs. EM, a two-tailed one-way ANOVA with Sidak's multiple comparisons adjustment
303 was used. For B/B vs. EM and for Control vs. B/B, a Kruskal-Wallis test with Dunn's multiple comparisons
304 adjustment was used. For Died: EM vs. SM: $p < 0.0001$, EM vs. B/B: $p = 1.0$, Control vs. B/B: $p = 0.043$, and
305 Control vs. SM: $p = 0.88$. For Survived: EM vs. SM: $p < 0.0001$, EM vs. B/B: $p = 1.0$, Control vs. B/B: $p = 0.043$,
306 and Control vs. SM: $p = 0.90$. *= $p < 0.05$. ****= $p < 0.0001$. ns=not significant. Source data are provided as a
307 Source Data file.

Supp. Figure 14







309 **Supplementary Figure 14: Effect of Macrophages in Educating Tumor Cells to Be Retained and**
310 **Survive in the Lung.**

311 **a:** Outline of the experimental design. Tumor cells (TC) were cultured alone or with macrophages for 48
312 hrs. After that, macrophages were purified via the CD11b MicroBeads (as described in Material and
313 Methods) separation column, and then injected into the tail vein of mice bearing a lung imaging window.
314 Then, the fate of each TCs was tracked using intravital imaging every 24 hrs for a period of 64 hr.

315 **b:** Kaplan-Meier survival curves showing the percentage of E0771-GFP tumor cells cultured alone (TC
316 alone), co-cultured with macrophages (TC with Mac), intravenously injected in mice (EM cells), or
317 spontaneously disseminated from a primary tumor (SM cells), observed under the WHRIL every 24 hr
318 over a period of 64 hrs. EM and SM data are from Figure 1c, but binned at a 24 hr interval, for comparison.
319 Tumor cells cultured alone: n=62 cells in 3 mice. Tumor cells co-cultured with macrophages: n=87 cells
320 in 4 mice. EM: n=60 cells in 3 mice. SM: n=28 cells in 3 mice. Log-rank (Mantel-Cox) tests. SM vs. TC
321 with Mac: p=0.0030, EM vs. TC alone: p=0.020, and TC alone vs. TC with Mac: p<0.0001. *=p<0.05.
322 **=p<0.01. ****=p<0.0001.

323 **c:** Percentage of extravascular E0771-GFP disseminated tumor cells that died or survived after
324 extravasation. Tumor cells cultured alone: n=27 tumor cells in 4 mice. Tumor cells co-cultured with
325 macrophages: n=38 cells in 4 mice. EM: n=19 cells in 4 mice. SM: n=31 tumor cells in 4 mice. EM and
326 SM data are from Figure 3b, but binned at a 24 hr interval, for comparison. For EM vs. TC alone and for
327 EM vs. SM died columns, a Kruskal-Wallis test with Dunn's multiple comparisons adjustment was used.
328 For Died: EM vs. TC alone: p=1.00, TC alone vs. TC with Mac: p=0.010, EM vs. SM: p=0.016, and SM
329 vs. TC with Mac: p=0.20. For Survived: EM vs. TC alone: p=0.82, TC alone vs. TC with Mac: p=0.019,
330 EM vs. SM: p=0.0003, and SM vs. TC with Mac: p=0.23. For all other statistical comparisons, two-sided
331 one-way ANOVA test with Sidak's multiple comparison adjustment were used. *=p<0.05. **=p<0.01.
332 ***=p<0.001. ns=not significant. Source data are provided as a Source Data file.

a Experimental Model (EM) in mice bearing a primary tumor (PT)
C57B6 model



334 **Supplementary Figure 15: Influence of the Primary Tumor on the Initial Steps of Lung Metastasis**


335 **a:** Outline of the experimental design. mCherry labeled tumor cells (E0771-mCherry) were injected into
336 the mammary gland and tumors allowed to develop for ~4 weeks after which the WHRIL was surgically
337 implanted and the mouse allowed to recover for 24 hrs. After that, GFP-labelled tumor cells (E0771-GFP)
338 were injected into the tail vein of the mouse, and their fate followed every 8 hrs for 48 hrs.

339 **b:** Kaplan-Meier survival curves showing the percentage of E0771-GFP tumor cells observed under the
340 WHRIL at each 8 hr time point over a period of 48 hrs. EM and SM data are from Figure 1c, but truncated
341 at 48hrs for comparison. EM: n=62 tumor cells analyzed in 3 mice. EM with primary tumor (EM+PT):
342 n=79 tumor cells analyzed in 4 mice. SM: n=29 tumor cells analyzed in 3 mice. Log-rank (Mantel-Cox)
343 tests. EM vs. EM + PT: p=0.0006 and EM + PT vs. SM: p=0.025. *= p<0.005. ***=p<0.001.

344 **c:** Percentage of E0771-GFP tumor cells in EM, EM+PT and SM groups, observed under the WHRIL that
345 extravasated between 0 and 48 hrs after arrival. EM and SM data are from Figure 1d, but truncated at
346 48hrs, for comparison). EM: n=89 tumor cells analyzed in 4 mice. EM with PT: n=79 tumor cells in 4 mice.
347 SM: n=29 tumor cells analyzed in 3 mice. Bar=mean. Error bars=±SEM. Two-tailed one-way ANOVA test
348 with Tukey's multiple comparisons adjustment. EM vs. EM + PT: p=0.040, EM vs. SM: p<0.021, and EM
349 + PT vs. SM: p=0.79. *=p<0.01. ns=not significant.

350 **d:** Percentage of extravascular E0771-GFP disseminated tumor cells that died or survived after
351 extravasation in EM, EM+PT and SM models. EM and SM data are from Figure 3b, but truncated at 48
352 hrs, for comparison. EM: n=26 tumor cells analyzed in 4 mice. EM with PT: n=44 tumor cells in 4 mice.
353 SM: n=31 tumor cells analyzed in 4 mice. Bar=mean. Error bars=±SEM. For all comparisons, two tailed
354 one-way ANOVA tests with Sidak's multiple comparisons adjustments were used. For Died: EM vs. EM
355 + PT: p=0.13, EM vs. SM: p<0.0007, and EM + PT vs. SM: p=0.017. For Survived: EM vs. EM + PT:
356 p=0.13, EM vs. SM: p<0.0007, and EM + PT vs. SM: p=0.17. *=p<0.05. ***=p<0.001. ns=not significant.
357 Source data are provided as a Source Data file.



Supp. Figure 16



358

359 **Supplementary Figure 16:** Uncropped blot for Figure 2c. Red boxes indicate the bands which were
360 cropped for Figure 2c. Source data are provided as a Source Data file.

Supp. Figure 17



362 **Supplementary Figure 17:** Uncropped blot for Supplemental Figure 5b. Red boxes indicate the bands
363 which were cropped for Supplemental Figure 5b. Source data are provided as a Source Data file.